Beijing Aosaikang Pharmaceutical Second Quarter 2024 Earnings: EPS: CN¥0.053 (vs CN¥0.10 loss in 2Q 2023)

Simply Wall St · 09/01 01:23

Beijing Aosaikang Pharmaceutical (SZSE:002755) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥474.1m (up 27% from 2Q 2023).
  • Net income: CN¥44.0m (up from CN¥89.9m loss in 2Q 2023).
  • Profit margin: 9.3% (up from net loss in 2Q 2023).
  • EPS: CN¥0.053 (up from CN¥0.10 loss in 2Q 2023).
earnings-and-revenue-growth
SZSE:002755 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Beijing Aosaikang Pharmaceutical Earnings Insights

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 4.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Beijing Aosaikang Pharmaceutical that you need to take into consideration.